This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Ubiquitin-specific peptidase 2 (USP2)	A study in cell culture suggests that inhibiting USP2 could help treat cancers that require high levels of cyclin D1 to ensure malignancy. In a human colorectal cancer cell line, small interfering RNA-mediated knockdown of USP2 reduced cyclin D1-mediated cell proliferation compared with that seen using control siRNA. Next steps could include screening for compounds that inhibit USP2 and evaluating them in animal models of cancer.	Patent and licensing status unavailable	Shan, J. <i>et al. Mol. Cell</i> ; published online Nov. 12, 2009; doi:10.1016/j.molcel.2009.10.018 Contact: Wei Gu, Columbia University, New York, N.Y. e-mail: wg8@columbia.edu
SciBX 2(47); doi:10.1038/scibx.2009.1724 Published online Dec. 10, 2009				